Published on 27 July 2021
A critical review of substitution policy for biosimilars in Canada
Author(s): Michael S Reilly, Esq, Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP
biosimilars, Canada, policy, substitution, switching
DOI: 10.5639/gabij.2021.1003.016
8.297 views